Back to search

Article

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environments

2025-12-22

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background and Objectives</h4> Blood-based biomarkers (BBMs), especially tau phosphorylated at threonine 217 (p-tau217), offer a minimally invasive approach to diagnose Alzheimer’s disease (AD) with strong potential for clinical implementation. However, the robustness and transferability of diagnostic thresholds across sites remain uncertain. This study aimed to evaluate BBMs’ ability to pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c9b5db8b-0b1b-53b1-ab63-ac979093574e
DOI
10.64898/2025.12.19.25342412
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsDOI 10.64898/2025.12.19.25342412
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity
Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity
Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity
CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity
Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity
Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinicsSemantic proximity
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin studySemantic proximity
Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity
Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity
Select a neighboring publication to make it the new centre.